Selective antagonists of a2a adenosine receptors

a technology of adenosine receptor and selective antagonist, which is applied in the field of compound and pharmaceutical composition, can solve the problems of poor bioavailability, poor selectiveness of sch58261, and poor soluble conten

Inactive Publication Date: 2012-02-09
ADENOSINE THERAPEUTICS
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

These compounds effectively block A2A receptor activity, providing therapeutic benefits for diseases like Parkinson's disease, cancer, and addictive disorders with improved stability and bioavailability compared to existing antagonists.

Problems solved by technology

However, each of these antagonists has important drawbacks.
SCH58261 is very poorly soluble and even its second-generation derivatives have marginal bioavailability.
ZM241385 not only is modestly selective but also has poor bioavailability.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Selective antagonists of a2a adenosine receptors
  • Selective antagonists of a2a adenosine receptors
  • Selective antagonists of a2a adenosine receptors

Examples

Experimental program
Comparison scheme
Effect test

example 2

4-[3-(6-Amino-9-cyclopentyl-9H-purin-2-yl)-prop-2-ynyl]-piperidine-1-carboxylic acid phenyl ester

[0182]Using the representative procedure for N9-alkylation above 4-[3-(6-amino-9H-purin-2-yl)-prop-2-ynyl]-piperidine-1-carboxylic acid phenyl ester (47 mg) gave the title compound as a white solid: yield 30 mg, 53%. 1H NMR (CD3OD) δ 8.20 (s, 1H), 7.39-7.32, 7.23-7.16, 7.11-7.06 (3×m, 5H), 4.90 (m, 1H), 4.42-4.14 (m, 2H), 3.08, 2.93 (2×m, 2H), 2.49 (d, 2H, J=6.3 Hz), 2.32-1.18, 2.07-1.73, 1.55-1.32 (3×m, 13H). 13C NMR (CD3OD) δ 157.0, 155.5, 152.9, 150.9, 147.5, 141.2, 130.3, 126.4, 122.9, 119.7, 85.9, 82.7, 57.5, 45.7, 45.5, 36.6, 33.6, 32.6, 32.4, 26.5, 24.8. LRMS ESI (M+H+) 445.2.

example 3

4-[3-(6-Amino-9-prop-2-ynyl-9H-purin-2-yl)-prop-2-ynyl]-piperidine-1-carboxylic acid 2-benzyloxy-ethyl ester

[0183]Using the representative procedure for N9-alkylation above 4-[3-(6-Amino-9H-purin-2-yl)-prop-2-ynyl]-piperidine-1-carboxylic acid 2-benzyloxy-ethyl ester (25 mg) gave the title compound as a white solid: yield 20 mg, 74%. 1H NMR (CD3OD) δ 8.20 (s, 1H), 7.32-7.20 (m, 5H), 5.01 (d, 2H, J=2.6 Hz), 4.53 (s, 2H), 4.27-4.09 (m, 4H), 3.67 (t, 2H, J=4.7 Hz), 2.98 (t, 1H, J=2.6 Hz), 2.91-2.73 (m, 2H), 2.42 (d, 2H, J=6.3 Hz), 2.91-1.73, 1.37-1.20 (2×m, 5H). 13C NMR (CD3OD) δ 157.0 (×2), 150.4, 147.9, 142.5, 139.5, 129.4, 128.8, 128.7, 119.3, 86.3, 82.5, 77.6, 75.9, 74.0, 69.5, 65.8, 45.1, 36.6, 33.9, 32.5, 26.5. LRMS ESI (M+H+) 473.2.

example 4

4-[3-(6-Amino-9-cyclopentyl-9H-purin-2-yl)-prop-2-ynyl]-piperidine-1-carboxylic acid 2-benzyloxy-ethyl ester

[0184]Using the representative procedure for N9-alkylation above 4-[3-(6-amino-9H-purin-2-yl)-prop-2-ynyl]-piperidine-1-carboxylic acid 2-benzyloxy-ethyl ester (21 mg) gave the title compound as a white solid: yield 10 mg, 41%. 1H NMR (CD3OD) δ 8.19 (s, 1H), 7.33-7.20 (m, 5H), 4.88 (m, 1H), 4.53 (s, 2H), 4.29-4.10 (m, 4H), 3.67 (t, 2H, J=4.7 Hz), 2 83 (m, 2H), 2.42 (d, 2H, J=6.0 Hz), 2.30-2.16, 2.05-1.70, 1.38-1.21 (3×m, 13H). 13C NMR (CD3OD) δ 157.0 (×2), 150.9, 147.5, 141.4, 139.5, 129.4, 128.8, 128.7, 119.7, 85.9, 82.7, 74.0, 69.5, 65.8, 57.5, 45.1, 36.6, 33.6, 32.5, 26.5, 24.8. LRMS ESI (M+H+) 503.4.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides compounds of formulae Ia and Ib:wherein R1-5, Q, X, Y, Z, p, q, and r are as defined herein. The compounds are potent and selective antagonists of A2A adenosine receptors (ARs). The invention further includes pharmaceutical compositions containing these compounds and methods of using the same.

Description

[0001]This application claims the benefit of U.S. Provisional Application No. 60 / 807,545, filed Jul. 17, 2006, the disclosure of which is incorporated herein in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to compounds and pharmaceutical compositions that are selective antagonists of the A2A adenosine receptor (AR). These compounds are useful as pharmaceutical agents.BACKGROUND OF THE INVENTION[0003]Selective antagonists of A2A adenosine receptors have proven to be effective for the treatment of Parkinson's disease (PD) both in animal models and in a human trial. (See Hauser et al, Neurology 2003, 61, 297-303). The first relatively selective A2AAR antagonists were the 8-styrylxanthines, for example KW-6002, which has low nanomolar affinity for the A2AAR and >100-fold selectivity for the A2AAR over the A1AR. KW-6002, entered clinical trials in 2002 as an agent for the treatment of PD. (See Bara-Jimenez et al, Neurology 2003, 61, 293-296) SCH58261, a pyraz...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K31/52A61P25/00A61P25/16A61P25/34A61P21/00A61P35/00A61P25/30A61P25/32C07D473/34A61P25/14
CPCC07D473/34A61P19/00A61P21/00A61P25/00A61P25/08A61P25/14A61P25/16A61P25/30A61P25/32A61P25/34A61P35/00A61P43/00
InventorBEAUGLEHOLE, ANTHONYRIEGER, JAYSON M.THOMPSON, ROBERT D.
OwnerADENOSINE THERAPEUTICS